申请人:Braje M. Wilfried
公开号:US20050137186A1
公开(公告)日:2005-06-23
The invention relates to tetrahydrobenzazepines of the general formula I
in which the variables Ar, A, B, Y, R
1
and R
2
have the meaninigs indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides.
The invention also relates to a pharmaceutical compositon that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond benefically to dopamine D
3
receptor antagonists or dopamine D
3
agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.
该发明涉及一般式I的四氢苯并氮杂环己烷,其中变量Ar、A、B、Y、R1和R2的含义如权利要求1所示,以及这些化合物的N-氧化物,这些化合物的生理耐受酸盐以及这些化合物的N-氧化物的生理耐受酸盐。该发明还涉及一种制剂,包括至少一种一般式I的四氢苯并氮杂环己烷化合物,一般式I的生理耐受酸盐,一般式I的化合物的N-氧化物和/或一般式I的N-氧化物的生理耐受酸盐,并且还涉及根据本发明用于治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的化合物的用途。根据本发明的化合物优选用于治疗中枢神经系统疾病,如精神分裂症和抑郁症,以及治疗肾功能障碍。